Pricing Log in Create free account

Acumen Pharmaceuticals, Inc. (ABOS) vs Adaptimmune Therapeutics PLC (ADAPY)

Acumen Pharmaceuticals, Inc. and Adaptimmune Therapeutics PLC are both Biotechnology companies. Acumen Pharmaceuticals, Inc. and Adaptimmune Therapeutics PLC are of similar size ($15.5M and $14.6M). Acumen Pharmaceuticals, Inc. has the higher net margin (0.00% vs −262.5%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, Acumen Pharmaceuticals, Inc. leads on 8 and Adaptimmune Therapeutics PLC on 6.

Valuation

Metric ABOS ADAPY Biotechnology median
P/E n/m n/m 10.60
P/S 11.08 0.08 9.40
P/B 0.46 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.35 n/m 0.66
EV/Sales (25.36) 0.08 9.02
Earnings yield (700.36%) (3,250.00%) (32.88%)
Free cash flow yield (553.34%) (3,648.13%) (23.13%)

Profitability

Metric ABOS ADAPY Biotechnology median
Gross margin 0.00% 94.81% 68.51%
Operating margin 0.00% (427.75%) 0.00%
Net margin 0.00% (262.46%) 0.00%
Free cash flow margin 0.00% (294.49%) 0.00%
Return on equity (162.72%) (1,349.52%) (51.96%)
Return on assets (91.28%) 0.00% (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ABOS ADAPY Biotechnology median
Revenue growth (TTM) — (53.99%) 6.76%
EPS growth (last fiscal year) (16.96%) 142.86% 29.88%
Revenue growth, 5-year CAGR — 8.40% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ABOS ADAPY Biotechnology median
Debt to equity 0.76 (0.36) 0.00
Current ratio 1.89 1.52 4.97
Net debt to EBITDA 0.69 0.47 1.01

Dividend

Metric ABOS ADAPY Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ABOS ADAPY Biotechnology median
Market cap 15.46m 14.55m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack